Menu Close


Chairs: Jesus Banales ( and Luca Fabris (

Mission of the WG:

The close association of PSC with CCA provides a unique opportunity to unravel the intricate mechanisms by which a chronic inflammatory epithelial lesion with prominent scarring progresses through dysplasia and carcinoma. Although this area has been actively investigated in the last few years, several challenges remain. This WG aims at addressing a number of issues, from the ability to detect early CCA onset in PSC to the identification of novel biomarkers with relevance in the pathophysiology sequence. The interdisciplinary collaboration including clinical and translational hepatologists, oncologists and molecular biologists provides a valuable asset for the development of proposals and published papers.

Project title


Contact info/email


ENS-CCA clinical Registry

Jesus Banales (San Sebastian, Spain)


Current status: >5000 patients included from 13 European countries. Recruiting new patients

Next-generation biomarkers for PSC/CCA: the role of circulating EV-proteins and metabolites

Pedro Rodrigues, Jesus Banales (San Sebastian, Spain)


Manuscript under revision (EV-proteins). Recruiting new patients for validation.


Manuscript under preparation (metabolites).

Role of fibrosis in promoting PSC progression to CCA – Development and characterisation of a mouse model of PSC/CCA

Luca Fabris, Massimiliano Cadamuro (Padua, Italy)


Recruiting human samples of PSC and PSC/CCA

GWAS for CCA and GBC

Lewis Roberts (Mayo Clinic, Rochester, MN)


Also recruiting PSC/CCA patients

Detection of CCA with protease activity probes

Jesse D. Kirkpatrick, Sangeeta N. Bhatia (MIT, Cambridge, MA)



Recruiting human bile and fresh frozen tissue samples of PSC and PSC/CCA

Template for studies in IPSCSG Malignancy Working Group 

  • Please find the template here

IPSCSG Publications

Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588.

– Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs. 2021 Apr;30(4):377-388.

– Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RIR, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW; Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology. 2021 Jun;73(6):2311-2325. 

– Diego F Calvisi, Luke Boulter, Javier Vaquero, Anna Saborowski, Luca Fabris, Pedro M Rodrigues, Cedric Coulouarn, Rui E Castro, Oreste Segatto, Chiara Raggi, Luc J.W. van der Laan, Guido Carpino, Benjamin Goeppert, Stephanie Roessler, Timothy Kendall, Mathias Evert, Ester Gonzalez-Sanchez, Juan W Valle, Arndt Vogel, John Bridgewater, Mitesh J Borad, Gregory J Gores, Lewis Roberts, Jose J.G. Marin, Jesper B Andersen, Domenico Alvaro, Alejandro Forner, Jesus M Banales, Vincenzo Cardinale, Rocio I.R. Macias, Silve Vicent, Xin Chen, Chiara Braconi, Monique M.A. Verstegen, Laura Fouassier. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. Nat Rev Gastroenterol Hepatol 2022 (in press).